{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:13:21Z","timestamp":1789726401779,"version":"4.0.1"},"reference-count":15,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T00:00:00Z","timestamp":1663286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:p>Purpose<\/jats:p>\n                  <jats:p>We report a probable case of morbilliform drug eruption secondary to fidaxomicin in a patient with Clostridioides difficile infection (CDI). Summary: A 62-year-old female presented to our institution\u2019s emergency department (ED) with symptoms consistent with Clostridioides difficile infection. The patient was prescribed 2\u00a0weeks of oral vancomycin for CDI prior to presentation. Given insufficient response to vancomycin, the patient was started on fidaxomicin with a planned 10-day course. After 2 doses of fidaxomicin, the patient developed a rash on her back that spread within 24\u00a0hours. The patient did not experience relief upon administration of a variety of medications for allergic reaction. Improvement was noted upon discontinuation of fidaxomicin. The Food and Drug Administration reports that &lt; 2% of adults treated with fidaxomicin experience a rash as an adverse effect. Conclusion: Fidaxomicin was a probable cause of morbilliform drug eruption in our patient with CDI. The patient improved upon discontinuation of fidaxomicin.<\/jats:p>","DOI":"10.1177\/08971900221078780","type":"journal-article","created":{"date-parts":[[2022,9,16]],"date-time":"2022-09-16T03:39:09Z","timestamp":1663299549000},"page":"993-997","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Fidaxomicin-Associated Hypersensitivity Reactions: Report of a Morbilliform Drug Eruption"],"prefix":"10.1177","volume":"36","author":[{"given":"Radha R.","family":"Molleti","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Memorial Hermann Memorial City Hospital, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique R.","family":"Bidell","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-4638","authenticated-orcid":false,"given":"Alexandra W.","family":"Tatara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,9,16]]},"reference":[{"key":"bibr1-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1403772"},{"key":"bibr2-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab549ciab549"},{"key":"bibr3-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir830"},{"key":"bibr4-08971900221078780","volume-title":"Dificid (Fidaxomicin) Package Insert","author":"","year":"2011"},{"key":"bibr5-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.12.003"},{"key":"bibr6-08971900221078780","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy7030135"},{"key":"bibr7-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0910812"},{"key":"bibr8-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr9-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2013.01.008"},{"key":"bibr10-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.01.033"},{"key":"bibr11-08971900221078780","doi-asserted-by":"publisher","DOI":"10.14423\/SMJ.0000000000000195"},{"key":"bibr12-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.03.032"},{"key":"bibr13-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1097\/IPC.0b013e318281d8d7"},{"key":"bibr14-08971900221078780","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cit719"},{"key":"bibr15-08971900221078780","volume-title":"FDA Adverse Event Reporting System (FAERS) Public Dashboard","author":"U.S. Food and Drug Administration"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900221078780","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900221078780","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900221078780","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:37:20Z","timestamp":1777509440000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900221078780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,16]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1177\/08971900221078780"],"URL":"https:\/\/doi.org\/10.1177\/08971900221078780","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,16]]}}}